Immune Homeostasis Maintenance Through Advanced Immune Therapeutics to Target Atherosclerosis

Area of Science:

• Immunology
• Cardiovascular Medicine
• Drug Development

Background:

• Atherosclerosis is a primary driver of coronary heart disease (CHD), imposing significant health and economic burdens.
• Current treatments targeting plasma lipids and inflammation have not sufficiently reduced CHD prevalence.
• Emerging research highlights immune system dysregulation in atherosclerosis pathogenesis.

Purpose of the Study:

• To review basic and translational research on novel immune-based strategies for atherosclerosis.
• To evaluate the potential of engineered immune leukocytes in treating atherosclerosis.
• To identify key challenges in translating these strategies into clinical applications.

Main Methods:

• Review of recent scientific literature on immune homeostasis and atherosclerosis.
• Analysis of preclinical and clinical studies involving engineered immune cells.
• Assessment of translational challenges in developing immune-based therapies.

Main Results:

• Traditional therapies targeting lipids and inflammation show limitations in controlling atherosclerosis.
• Disrupted immune homeostasis is increasingly recognized as a key factor in atherosclerosis development.
• Engineered immune leukocytes represent a promising novel therapeutic avenue.

Conclusions:

• Restoring immune homeostasis through engineered immune cells offers a new paradigm for atherosclerosis treatment.
• Further translational research is crucial to overcome challenges in developing these advanced therapies.
• This approach holds potential for more effective management of coronary heart disease.